Physician profile
John N Blixt
NPI 1114213204
$2,427.71
in general payments reported to CMS, 2019-2025
24 companies · $424 in 2025
The $424 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $614 · 2020: $551 · 2021: $340 · 2022: $86.04 · 2023: $125 · 2024: $288 · 2025: $424.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $756 · Education: $80.86.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $755.84 |
| Education | $80.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $607.41 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $352.69 | 2019-2025 | Jascayd |
| Mylan Specialty L.P. | $228.10 | 2019-2024 | Yupelri |
| Astrazeneca Pharmaceuticals Lp | $218.70 | 2019-2025 | Airsupra, Fasenra, Tezspire |
| Actelion Pharmaceuticals US, INC. | $164.09 | 2019-2025 | Opsumit |
| Insmed, INC. | $131.63 | 2019-2025 | Arikayce |
| Regeneron Healthcare Solutions, INC. | $130.47 | 2024-2025 | Dupixent |
| Genentech USA, INC. | $96.51 | 2019 | |
| Grifols USA, LLC | $72.55 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $58.95 | 2021-2025 | Glassia |
| Viatris Specialty LLC | $50.91 | 2025 | Yupelri |
| Philips North America LLC | $49.30 | 2019-2020 | |
| Amgen INC. | $36.86 | 2023-2024 | Tezspire |
| Jazz Pharmaceuticals INC. | $30.90 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $30.57 | 2019-2020 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inogen, INC. | $26.51 | 2025 | |
| Nabriva Therapeutics, Plc | $22.84 | 2021 | |
| Pulmonx Corporation | $22.74 | 2021 | |
| Baxter Healthcare | $21.39 | 2023 | Hillrom - Life 2000 Ventilation System |
| Electromed, INC. | $19.62 | 2025 | Smartvest |
| Shire North American Group INC | $16.84 | 2019 | |
| Genzyme Corporation | $13.33 | 2022 | |
| Sunovion Pharmaceuticals INC. | $13.20 | 2019 | |
| Pfizer INC. | $11.60 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Blixt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.